Safety and Pharmacokinetics of Intravenous Zanamivir Treatment in Hospitalized Adults With Influenza: An Open-label, Multicenter, Single-Arm, Phase II Study
Francisco M. Marty(Brigham and Women's Hospital), A. F. Peppercorn, V. Thamlikitkul(Siriraj Hospital), C. Y. Man, H. H. Zhao, F. Alvarez-Lerma(Parc de Salut), David Brealey(UCL Biomedical Research Centre), S. Weller(GlaxoSmithKline (India)), Bruno François(Inserm), Philip Yates(GlaxoSmithKline (United Kingdom)), J. A. Lorente(Hospital Universitario de Getafe), C. van der Horst(Johns Hopkins University Center for AIDS Research), Denis Garot(Centre Hospitalier Universitaire de Tours)
Cited by 55
Related Papers
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
The SOFA score—development, utility and challenges of accurate assessment in clinical trials
|Critical Care|2019|976
Hydrocortisone plus Fludrocortisone for Adults with Septic Shock
|New England Journal of Medicine|2018|894
Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
|New England Journal of Medicine|2005|890